Zacks Investment Research upgraded shares of Akcea Therapeutics, Inc. (NASDAQ:AKCA) from a sell rating to a hold rating in a research note released on Thursday.

According to Zacks, “Akcea Therapeutics, Inc. is a biopharmaceutical company. It focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. The Company’s drug pipeline consists of volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx which are in clinical stage. Akcea Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “

Several other equities analysts have also recently weighed in on AKCA. Wells Fargo & Company assumed coverage on shares of Akcea Therapeutics in a research report on Tuesday, August 8th. They set an outperform rating and a $27.00 price objective on the stock. Cowen and Company assumed coverage on shares of Akcea Therapeutics in a research report on Tuesday, August 8th. They set an outperform rating on the stock. Stifel Nicolaus assumed coverage on shares of Akcea Therapeutics in a research report on Tuesday, August 8th. They set a buy rating and a $19.00 price objective on the stock. Finally, BMO Capital Markets assumed coverage on shares of Akcea Therapeutics in a research report on Tuesday, August 8th. They set an outperform rating and a $25.00 price objective on the stock. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of Buy and a consensus target price of $24.00.

Akcea Therapeutics (AKCA) traded up $1.04 during midday trading on Thursday, hitting $19.22. The company’s stock had a trading volume of 236,700 shares, compared to its average volume of 288,709. Akcea Therapeutics has a 52 week low of $8.10 and a 52 week high of $31.23.

TRADEMARK VIOLATION WARNING: “Akcea Therapeutics, Inc. (AKCA) Upgraded to “Hold” at Zacks Investment Research” was posted by Watch List News and is the property of of Watch List News. If you are viewing this article on another website, it was stolen and republished in violation of US & international copyright and trademark laws. The original version of this article can be read at https://www.watchlistnews.com/akcea-therapeutics-inc-akca-upgraded-to-hold-at-zacks-investment-research/1698830.html.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Legal & General Group Plc purchased a new position in Akcea Therapeutics during the 3rd quarter worth approximately $111,000. Strs Ohio purchased a new position in Akcea Therapeutics during the 3rd quarter worth approximately $118,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Akcea Therapeutics during the 3rd quarter worth approximately $180,000. Nationwide Fund Advisors purchased a new position in Akcea Therapeutics during the 3rd quarter worth approximately $209,000. Finally, Wells Fargo & Company MN purchased a new position in Akcea Therapeutics during the 3rd quarter worth approximately $222,000. Hedge funds and other institutional investors own 0.02% of the company’s stock.

Akcea Therapeutics Company Profile

Akcea Therapeutics, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company’s drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc (Ionis).

Receive News & Ratings for Akcea Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akcea Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.